ArticleScientific reports2021
Catestatin in innate immunity and Cateslytin-derived peptides against superbugs.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Serum Catestatin Level as a Novel Biomarker of Oral Lichen Planus.Medical sciences (Basel, Switzerland) · 2026Article
- The role of chromogranin A cleavage products in onset of type 1 and 2 diabetes.Frontiers in clinical diabetes and healthcare · 2026Review
- Antimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens.Annals of medicine and surgery (2012) · 2025Review
- Catestatin: Antimicrobial Functions and Potential Therapeutics.Pharmaceutics · 2023Review
- Serum Catestatin Level as a Stratification Assessment Tool in Non-Critical COVID-19 Patients.International journal of environmental research and public health · 2023Article
- More than skin deep: cyclic peptides as wound healing and cytoprotective compounds.Frontiers in cell and developmental biology · 2023Review
- Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care.Pharmaceutics · 2022Review
- Prognostic Value of Catestatin in Severe COVID-19: An ICU-Based Study.Journal of clinical medicine · 2022Article
- The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis.International journal of molecular sciences · 2022Article
- Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality.Frontiers in immunology · 2022Article
- The antimicrobial peptides secreted by the chromaffin cells of the adrenal medulla link the neuroendocrine and immune systems: From basic to clinical studies.Frontiers in immunology · 2022Review
- Putative regulation of macrophage-mediated inflammation by catestatin.Trends in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogranin A (CgA) is the precursor of several antimicrobial peptides, such as Catestatin (Cts, bovine CgA344-364), initially described as a potent inhibitor of catecholamines. This peptide displays direct antimicrobial activities and contributes to immune system regulation. The aim of the present study is to investigate a designed peptide based on Cts to fight infections against superbugs and more particularly Staphylococcus aureus. In addition to Cateslytin (Ctl, bovine CgA344-358), the active domain of Catestatin, several peptides including dimers, D-isomer and the new designed peptide DOPA-K-DOPA-K-DOPA-TLRGGE-RSMRLSFRARGYGFR (Dopa
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.